Blueshift Asset Management LLC Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Blueshift Asset Management LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 339 shares of the biopharmaceutical company’s stock, valued at approximately $356,000.

A number of other institutional investors have also made changes to their positions in the stock. Sachetta LLC boosted its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $26,000. Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Finally, Family Firm Inc. purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Royal Bank of Canada dropped their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,107.29.

Regeneron Pharmaceuticals Trading Up 0.2 %

REGN opened at $754.87 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The business’s 50 day moving average is $913.54 and its two-hundred day moving average is $1,020.69. The firm has a market cap of $82.95 billion, a price-to-earnings ratio of 18.68, a price-to-earnings-growth ratio of 2.91 and a beta of 0.15.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.